960 Randomized multicenter study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer

• Tanios Bekaii-Saab,
• Todd Bauer,
• Gina Petroni,
• Osama Rahma,
• Rawad Elias,
• Craig Slingluff,
• Mathew Katz,
• Brian Wolpin,
• Chee-Chee Stucky,
• Andressa Dias-Costa,
• Jonathan Nowak,
• Lenehan Patrick,
• Stephanie Dougan

Affiliations

Tanios Bekaii-Saab

Aff1 grid.261331.40000000122857943The Ohio State University Columbus OH USA

Todd Bauer

Aff106 grid.240145.60000000122914776University of Texas MD Anderson Cancer Center Houston TX USA

Gina Petroni

Aff426 grid.27755.32000000009136933XUniversity of Virginia Charlottesville VA USA

Osama Rahma

Center for Cancer Therapeutic Innovation, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Rawad Elias

Aff1 0000 0004 0367 5222grid.475010.7Sections of Hematology Oncology and geriatricsBoston University School of Medicine Boston MA USA

Craig Slingluff

University of Virginia, charlottesville, VA, USA

Mathew Katz

2MD Anderson Cancer Center, Houston, TX, USA

Brian Wolpin

4Dana-Farber/Harvard Cancer Center, Boston, MA, USA

Chee-Chee Stucky

5Mayo Clinic, Phoenix, AZ, USA

Andressa Dias-Costa

4Dana-Farber/Harvard Cancer Center, Boston, MA, USA

Jonathan Nowak

4Dana-Farber/Harvard Cancer Center, Boston, MA, USA

Lenehan Patrick

4Dana-Farber/Harvard Cancer Center, Boston, MA, USA

Stephanie Dougan

4Dana-Farber/Harvard Cancer Center, Boston, MA, USA